Skip to main contentSkip to navigationSkip to search

ENEA 2025

Long-term and sustained biochemical control of acromegaly and improved quality of life with CAM2029 octreotide subcutaneous depot: final analysis of the core phase of ACROINNOVA 2

Click the material you wish to view

ACROINNOVA 2 poster

PDF

ACROINNOVA 2 poster supplementary

PDF

See all posters presented at
ENEA 2025

Explore more

Disease areas

Camurus is committed to improving treatment outcomes and quality of life for people with severe and chronic diseases.

Congresses

Discover Camurus’ engagement at conducted and upcoming international medical conferences and events.